Exelon clinical trials

The results of the trials showed that patients treated with Exelon experienced a significantly smaller increase in their test score compared to those treated with placebo, suggesting that Exelon successfully reduced the symptoms of AD.

Exelon was approved for marketing as a patch based on a Phase 3 clinical trial called IDEAL, which demonstrated an increase in efficiency of the patch compared to the capsule form of the drug. The results of the study were published in the scientific journal Neurology.

Since June , the Exelon patch is approved to treat all stages of AD , based on the results of another clinical trial called ACTION NCT , which showed a significant improvement in cognition and daily function of Exelon-treated patients compared to those treated with placebo.

The most common side effects associated with taking Exelon are nausea sickness , vomiting, anorexia lack of appetite , dyspepsia indigestion , dizziness, and asthenia weakness. Some patients also report that the Exelon patch causes a skin reaction at the site of application such as redness or itching. It does not provide medical advice, diagnosis or treatment. If dosing is interrupted for more than 3 days, restart treatment with the 4. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase.

Adverse events associated with the use of Exelon patch may include, but are not limited to, the following:. This randomized, double-blind trial enrolled 1, subjects who were placed in one of the following cohorts: Exelon Patch 9. The trial was divided into a week titration phase followed by an 8-week maintenance phase.

At weeks the differences in the mean ADAS-Cog change scores for the Exelon-treated subjects compared to the subjects on placebo, were 1. Both endpoints reached statistical significance compared to placebo. Examination MMSE score greater than or equal to 10 and less than or equal to 24]. Alzheimer's Patch Cognitive Decline. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Alzheimer Disease. Phase 3. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Triple Participant, Care Provider, Investigator. Study Start Date :. Actual Primary Completion Date :. Actual Study Completion Date :.

Springfield, Massachusetts, United States, Traverse City, Michigan, United States, Ocean Springs, Mississippi, United States, Learn more about the modernization effort. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. First Posted : May 18, Results First Posted : February 28, Last Update Posted : February 28,